Enteric fever, encompassing both typhoid and paratyphoid fever, remains a significant global health concern. Despite advances in diagnostic methods and treatment regimens, the disease continues to pose challenges due to evolving antibiotic resistance and non-specific clinical presentation. This article outlines the latest approach to diagnosing and treating enteric fever.
Diagnosis of enteric fever has traditionally relied on blood culture, which remains the gold standard. However, its sensitivity varies from 40-80%, necessitating the need for more accurate tests. Molecular diagnostic techniques, such as polymerase chain reaction (PCR), offer higher sensitivity and specificity. Novel rapid diagnostic tests (RDTs) based on antigen detection are also promising, with the Typhidot test showing considerable utility in resource-limited settings.
The rise of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains of Salmonella Typhi has made treatment more complex. Fluoroquinolones, once the drug of choice, are now less effective due to resistance. Current guidelines recommend using third-generation cephalosporins like ceftriaxone or cefixime, or azithromycin as first-line treatment. In cases of XDR strains, carbapenems or azithromycin are recommended.
Vaccination remains a key preventive measure. The World Health Organization recommends the typhoid conjugate vaccine (TCV) for children over six months in endemic areas. The older Vi polysaccharide vaccine is recommended for travellers to endemic areas, but does not provide long-term protection like TCV.
Enteric fever continues to be a global health challenge. Accurate diagnosis is pivotal and can be enhanced with molecular techniques and RDTs. Treatment is complicated by increasing antibiotic resistance, necessitating vigilant antibiotic stewardship. Vaccination remains a crucial component of prevention. As healthcare professionals, staying abreast of these evolving strategies is essential in managing this persistent disease.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation